NICE has recommended the twice-daily Calquence (Acalabrutinib) for the treatment of certain adult patients with chronic lymphocytic leukaemia (CLL).
It has been approved as monotherapy for CLL if there is a 17p deletion or TP53 mutation or if fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable…
